Skip to content
Biotechnology

BioMed X and AbbVie Start New Research Project in the USA

The BioMed X Institute 3 mins read

BioMed X inaugurates its new institute in the USA with a research project on complex ex vivo models of tissue inflammation in collaboration with AbbVie.

NEW HAVEN, CT / ACCESSWIRE / October 31, 2023 / BioMed X, an independent biomedical research institute, announces the start of a research project in collaboration with AbbVie to be hosted by the new BioMed X Institute in New Haven, CT, USA. The project aims to generate an organotypic human arterial model with sufficient complexity to recapitulate key characteristics of chronic autoimmune disease onset, progression, and resolution, with the long-term goal of advancing patient treatment.

Dr. Alicia Cutler is the Group Leader of the "Complex Human Ex Vivo Models of Tissue Inflammation" project. Before accepting this position at BioMed X, Alicia was a Research Associate in the Department of Molecular, Cell, and Developmental Biology at the University of Colorado Boulder, USA. "My initial training in biochemistry and stem cell biology positioned me to expand my research interests towards tissue engineering and bioprinting. I am very excited about this opportunity to start a new research group on this topic with the support of BioMed X and AbbVie," explains Alicia.

The new BioMed X Institute is located in New Haven, CT, in the Elm City Bioscience Center, neighboring Yale University, and will be managed by Mark Johnston, an experienced biotech CEO and entrepreneur. "Alicia was the winner of a competitive boot camp we conducted with our partners at AbbVie, following BioMed X's unique crowdsourcing model. I am thrilled she accepted to be our first BioMed X US Group Leader," says Mark Johnston, Chief Executive Officer of BioMed X USA.

This is already the second research collaboration between BioMed X and AbbVie. Dr. Christian Tidona, Founder and Managing Director of the BioMed X Institute, explains: "After 10 years of success stories at our institute in Heidelberg, Germany, we have decided to extend our operations overseas. Our first project with AbbVie in Heidelberg was successfully completed in 2019, focusing on Tau-mediated neurodegeneration in Alzheimer's disease. We are grateful that AbbVie has agreed to partner with us again for our first project on US territory," adds Tidona.

"We are pleased to expand our collaboration with BioMed X to the US and continue the work to enhance our understanding of human disease biology. This is a unique opportunity to create the complex in vitro model systems needed to advance the field of immunology research and beyond," said Dr. Timothy Radstake, Vice President & Global Head, Immunology Discovery Research at AbbVie.

About BioMed X

BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world's brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds - academia and industry - and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.

Contact Information

Flavia-Bianca Cristian
Recruiting & Communications Manager
fbc@bio.mx
+49 6221 426 11 706

Related Images

SOURCE: BioMed X Institute

.


View source version on accesswire.com:
https://www.accesswire.com/797155/biomed-x-and-abbvie-start-new-research-project-in-the-usa

More from this category

  • Biotechnology, Environment
  • 18/04/2024
  • 11:03
Wilderlands

Wilderlands protects 100,000 square metres of vulnerable Australian habitat through biodiversity credits.

Wilderlands have reached a major milestone becoming the world’s fastest voluntary biodiversity credit developer to retire over 100,000 units which will protect over 10…

  • Contains:
  • Biotechnology
  • 18/04/2024
  • 00:22
Derm-Biome Pharmaceuticals, Inc

Derm-Biome Pharmaceuticals’ topical therapy shows positive results in preclinical skin cancer trial: drug prevents the development of precancerous skin conditions and treats existing skin cancers with no observable side effects.

VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) -- The rates of precancerous skin conditions and skin cancers are soaring in many parts of the world. Actinic keratosis (AK) is the most common form of precancer, with over 40 million Americans a year developing this condition. Treating AKs before the cells become cancerous and spread to other parts of the body is crucial. For those patients with multiple AKs, common treatment options are chemotherapy creams and photodynamic therapy. Although effective, these treatments come with significant side effects, such as redness, blistering, and peeling, with recovery times that can be lengthy and uncomfortable. The global actinic keratosis treatment market size is projected to reach as high as $10 billion USD by 2031, fuelled by increasing cases of AK and rising healthcare spending.Derm-Biome Pharmaceuticals is a Vancouver-based biopharmaceutical…

  • Biotechnology, Medical Health Aged Care
  • 16/04/2024
  • 11:26
Island Pharmaceuticals

Island reports highly positive new data from ISLA-101 Single Ascending Dose study

Island reports highly positive pharmacokinetic data and reconfirms strong safety / tolerability data for ISLA-101 from its 24-subject Single Ascending Dose clinical study Data analysis shows required levels of ISLA-101 concentration in the blood were observed after only a single dose, achieving the study's purpose This important new data is being used to prepare for Island's planned Phase 2a clinical trial in dengue fever MELBOURNE Australia, 16 April 2024: Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; “Island”; “the Company”) is pleased to announce highly encouraging pharmacokinetics (PK) data from its ISLA-101 Single Ascending Dose study. ISLA-101 is…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.